AL Amyloidosis

#AL Amyloidosis #Clinical trial #Financing

Protego raises $130 million to advance AL amyloidosis treatment 

Biotechnology company Protego Biopharma has raised $130 million to advance its first-in-class AL amyloidosis programme to clinical trial.  The proceeds from the over-subscribed Series B financing round will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis. PROT-001 works by stabilising immunoglobulin light chains and preventing amyloid buildup, addressing disease at its root cause… Read More

#Business & Investment #News